Citation

Drug. Ther. Persp. 2014; 30(11): 386-389.

Copyright

(Copyright © 2014)

DOI

10.1007/s40267-014-0160-2

PMID

unavailable

Abstract

In major depressive disorder, lithium can be used as augmentation in antidepressant non-responders, as second-line long-term therapy for the prevention of new depressive episodes, and for the prevention of suicide. Lithium use requires individualized dosages to achieve therapeutic lithium concentrations, regular monitoring of serum concentrations and patient education. © 2014, Springer International Publishing Switzerland.

Language: en

Keywords

human; suicide; bipolar disorder; major depression; lithium; mood disorder; patient education; serum; antidepressant agent; serotonin uptake inhibitor; tricyclic antidepressant agent; unclassified drug; somnolence; coma; psychotropic agent; practice guideline; convulsion; drug safety; placebo; mental patient; drug blood level; nonsteroid antiinflammatory agent; drug efficacy; diarrhea; tremor; blood level; maintenance therapy; alopecia; ataxia; drug monitoring; nausea and vomiting; dipeptidyl carboxypeptidase inhibitor; laboratory test; monotherapy; dizziness; rigor; treatment response; dysarthria; Article; diuretic agent; lithium salt; skin disease; treatment duration; clinical trial (topic); lithium aspartate; lithium citrate; lithium sulfate